First Trust Direct Indexing L.P. Has $993,000 Stock Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

First Trust Direct Indexing L.P. lifted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 7,523 shares of the medical equipment provider’s stock after purchasing an additional 184 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Zimmer Biomet were worth $993,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of ZBH. Community Bank & Trust Waco Texas increased its holdings in Zimmer Biomet by 2.4% in the 1st quarter. Community Bank & Trust Waco Texas now owns 5,876 shares of the medical equipment provider’s stock valued at $776,000 after buying an additional 140 shares during the period. Exchange Capital Management Inc. increased its stake in Zimmer Biomet by 24.5% in the first quarter. Exchange Capital Management Inc. now owns 28,571 shares of the medical equipment provider’s stock valued at $3,771,000 after acquiring an additional 5,614 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH raised its position in Zimmer Biomet by 4.4% during the first quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH now owns 10,268 shares of the medical equipment provider’s stock valued at $1,355,000 after purchasing an additional 430 shares in the last quarter. AlphaMark Advisors LLC lifted its stake in Zimmer Biomet by 1,880.0% during the first quarter. AlphaMark Advisors LLC now owns 990 shares of the medical equipment provider’s stock worth $131,000 after purchasing an additional 940 shares during the last quarter. Finally, AMI Investment Management Inc. acquired a new stake in shares of Zimmer Biomet in the 1st quarter valued at $210,000. Institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of research analyst reports. Argus raised Zimmer Biomet from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a report on Tuesday, May 21st. Evercore ISI dropped their target price on shares of Zimmer Biomet from $130.00 to $115.00 and set an “in-line” rating for the company in a report on Tuesday. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Thursday, May 30th. Truist Financial lowered their price objective on shares of Zimmer Biomet from $137.00 to $130.00 and set a “hold” rating for the company in a research report on Friday, May 3rd. Finally, Citigroup raised their target price on shares of Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $131.76.

Zimmer Biomet Stock Up 0.3 %

Zimmer Biomet stock opened at $106.58 on Friday. The firm has a market cap of $21.93 billion, a price-to-earnings ratio of 23.07, a PEG ratio of 1.92 and a beta of 1.01. Zimmer Biomet Holdings, Inc. has a 52-week low of $102.00 and a 52-week high of $144.13. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.80 and a current ratio of 1.66. The firm has a 50 day moving average price of $114.14 and a two-hundred day moving average price of $120.85.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.94 earnings per share for the quarter, topping analysts’ consensus estimates of $1.87 by $0.07. Zimmer Biomet had a net margin of 12.93% and a return on equity of 12.70%. The business had revenue of $1.89 billion during the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter last year, the firm earned $1.89 earnings per share. Zimmer Biomet’s quarterly revenue was up 3.2% on a year-over-year basis. Equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.1 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 31st. Investors of record on Wednesday, June 26th will be paid a dividend of $0.24 per share. The ex-dividend date of this dividend is Wednesday, June 26th. This represents a $0.96 annualized dividend and a yield of 0.90%. Zimmer Biomet’s dividend payout ratio is currently 20.78%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.